Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.34 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | CDC14B | O60729 | 2/20 | 0.31 |
| ▸ | CDC14A | Q9UNH5 | 2/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20205564 | 0.96 | ALOX5 (0.36) | ALOX5PRKDCAHRKDM4EMEN1 | |
| SCHEMBL20205343 | 0.94 | ALOX5 (0.31) | ALOX5HCRTR1 | |
| SCHEMBL20205718 | 0.92 | TDP1 (0.33) | AHRHCRTR1 | |
| SCHEMBL20205547 | 0.91 | ALOX5 (0.35) | ALOX5PRKDCAHRKDM4EMEN1 | |
| SCHEMBL20205736 | 0.90 | CDC14B (0.37) | ALOX5CDC14BCDC14A | |
| SCHEMBL24649880 | 0.90 | CDC14B (0.38) | ALOX5AHRMEN1MAPTHPGD | |
| SCHEMBL20205344 | 0.90 | ALOX5 (0.33) | ALOX5PRKDCAHRKDM4EMEN1 | |
| SCHEMBL20205305 | 0.90 | ALOX5 (0.33) | ALOX5PRKDCAHRKDM4EMEN1 | |
| SCHEMBL24649632 | 0.88 | GPR84 (0.34) | ALOX5CDC14BCDC14A | |
| SCHEMBL24649679 | 0.88 | CDC14B (0.33) | ALOX5CDC14BCDC14A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453680-B2 | Bisbenzofuran-fused indeno[1,2-B]fluorene derivatives and related compounds as materials for organic electroluminescent devices (OLED) | MERCK PATENT GMBH (DE) | 2022-09-27 | — | — | US | disclosed |
| WO-2018095940-A1 | BISBENZOFURAN-FUSED INDENO[1,2-B]FLUORENE DERIVATIVES AND RELATED COMPOUNDS AS MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES (OLED) | MERCK PATENT GMBH (DE) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11453680-B2 | Bisbenzofuran-fused indeno[1,2-B]fluorene derivatives and related compounds as materials for organic electroluminescent devices (OLED) | OCIAD2, OCIAD1, JUND | ALOX5 354/4885PRKDC 4001/4885AHR 1079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.